Deals, Development and Manufacturing

The collaboration will see Moderna and CytomX work together to develop mRNA-based conditionally activated therapeutics.

Agilent’s acquisition of Avida grants them access to high-performance enrichment workflows that enable NGS approaches for studying cancer.

Merck, known as MSD outside of the United States and Canada, will pay Kelun-Biotech up to $9l3 billion for seven early-stage oncology treatments.

The latest report from Clarivate has been published, highlighting 15 potential blockbusters to watch out for in 2023, the majority of which are personalized medicines.

GSK and Wave Life Sciences have entered into a collaboration to drive drug discovery and development for novel genetic targets.

AbCellera and Rallybio are teaming up to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases.

Under the collaboration between Vertex and Entrada, the companies will work on discovering and developing intracellular endosomal escape vehicle therapeutics for myotonic dystrophy type 1.

Amgen’s $27.8 billion acquisition of Horizon Therapeutics, an Irish biotechnology company, is one of the largest of 2022.

The partnership will see the pharma giants partner with researchers from A*STAR and various Singapore universities.

Pharmaceutical Technology Europe got the scoop on Agilent's new Dissolution Testing Centre of Excellence in Craven Arms, UK.

Anti-obesity drugs have the potential to be the next blockbusters, according to market analysis.

Merck will use BigHat’s AI/machine learning-enabled platform to design candidates for up to three drug discovery programs.

AstraZeneca inked a deal worth up to $320 million to purchase Neogene Therapeutics, a biotech start-up focused on T-cell receptor therapies.

The agreement will see Immutep and Merck KGaA, Darmstadt, Germany jointly fund the INSIGHT-005 study.

Merck will purchase Imago BioSciences, a biotechnology company focused on bone marrow disorders, for approximately $1.35 billion.

The collaboration will see the companies develop investigational next-generation bispecific immunotherapies for cancer.

Biotech startup, Cradle, has raised $5.4 million in seed funding with an AI-enabled design platform that allows for the synthetic building of cell factories to produce proteins.

CellVax Therapeutics has selected Theragent, a new CDMO, to manufacture clinical trial material for a new Phase II prostate cancer immunotherapy drug candidate.

The deal will see Sanofi use Insilico’s AI drug discovery platform to advance up to six new drug development candidates.

Indivior’s acquisition of Opiant grants them access to the company’s portfolio of investigational opioid overdose reversal agent, OPNT003.

The collaboration will see Shimadzu and UMG develop new clinical laboratory methods using LC-MS for TDM analysis.

Gerresheimer and Nelson Labs will work together to conduct extractables and leachables testing on upcoming primary packaging solutions.

Under this deal, Merck, known as MSD outside of the United States and Canada, will select Veeva products for industry-specific software and data.

Johnson & Johnson’s acquisition of Abiomed, a provider of heart pump technologies, is designed to bolster their position in the medical technology sector.

Lonza and Singzyme will use Singzyme’s enzymatic conjugation platform to develop novel bioconjugates.

Purolite and Repligen have extended their existing ligand partnership through 2032.

The newly formed partnership between CSafe and BioLife will expand cold chain supply chain solutions for the cell and gene therapy market.

Under two new agreements, Societal CDMO will offer analytical, technical transfer, formulation, manufacturing, and packaging services for novel therapeutics.

Under the new collaboration with Tempus, GSK will have access to de-identified patient data to accelerate drug discovery, improve clinical trial design, and speed up enrollment.

Aenova Group and Microcaps are partnering to enable new customized formulations for product development and life cycle management solutions.